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AIM
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1) receptor modulator which is currently being developed
for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a
favourable cardiac safety proﬁle in preclinical, phase I and II studies. The aim of the current study was to characterize the cardiac
effects of amiselimod by directly comparing it with ﬁngolimod and placebo.
METHODS
A total of 81 healthy subjects aged 18–55 years were equally randomized to receive amiselimod 0.4 mg, amiselimod 0.8 mg,
placebo or ﬁngolimod 0.5 mg once daily for 28 days. The chronotropic/dromotropic and inotropic effects were evaluated using
intensive Holter electrocardiogram and echocardiography.
RESULTS
Unlike ﬁngolimod, neither amiselimod dose exerted acute (1–6 h) negative chronotropic effects on Days 1 and 2. The lowest nadir
mean hourly heart rate was observed on Day 14 in the amiselimod 0.4mg group (least squares mean difference:4.40 bpm, 95%
conﬁdence interval 7.15, 1.66) and Day 7 in the 0.8 mg group [3.85 bpm (6.58, 1.11)] compared with placebo, but
these changes were smaller than those with ﬁngolimod on Day 1 [6.49 bpm (8.95, 4.02)]. No clinically signiﬁcant
bradyarrhythmia or cardiac functional abnormalities were observed in either amiselimod group. Both amiselimod doses were well
tolerated and no serious adverse events were reported. Fingolimod was also generally well tolerated, although one subject was
withdrawn owing to highly frequent 2:1 atrioventricular blocks on Day 1.
CONCLUSION
The study demonstrated a more favourable cardiac safety proﬁle for amiselimod than ﬁngolimod when administered over 28 days
in healthy subjects.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Fingolimod is the ﬁrst sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of relapsing–
remitting multiple sclerosis (RRMS).
• At initiation of ﬁngolimod treatment, at least 6 h of cardiac monitoring is required due to its known negative
chronotropic effect.
• Amiselimod is a selective S1P1 receptor modulator which has been shown to have a strong anti-inﬂammatory effect in
patients with RRMS, yet without any signiﬁcant cardiac adverse effects.
WHAT THIS STUDY ADDS
• Amiselimod demonstrated a more favourable cardiac safety proﬁle than ﬁngolimod over 28-day administration.
• Unlike ﬁngolimod, there were no clinically relevant cardiac adverse effects observed with amiselimod at doses up to
0.8 mg. Dose titration was not necessary.
• Cardiac safety monitoring after the ﬁrst dose of amiselimod is therefore considered unwarranted.
Tables of Links
TARGETS
G protein-coupled receptors [2]
S1P1 receptor
S1P2 receptor
S1P3 receptor
S1P4 receptor
S1P5 receptor
Voltage-gated ion channels [3]
G-protein-activated inward-rectiﬁer K channel (Kir3.1)
G-protein-activated inward-rectiﬁer K channel (Kir3.2)
G-protein-activated inward-rectiﬁer K channel (Kir3.3)
G-protein-activated inward-rectiﬁer K channel (Kir3.4)
LIGANDS
Sphingosine 1-phosphate
Amiselimod
Fingolimod
Fingolimod phosphate
Siponimod (BAF312)
Ponesimod
Ozanimod (RPC-1063)
These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to PHARMACOLOGY
2015/16 [2, 3].
Introduction
Fingolimod (FTY720, Gilenya®) is the ﬁrst sphingosine
1-phosphate (S1P) receptor modulator approved for the treat-
ment of relapsing–remitting multiple sclerosis (RRMS) [4].
The therapeutic effects of ﬁngolimod are primarily obtained
by functional antagonism of the lymphocytic sphingosine
1-phosphate 1 (S1P1) receptor, which consequently inhibits
S1P1-dependent lymphocyte egress from secondary lym-
phoid organs to the periphery, decreases circulating
lymphocytes including autoreactive T cells, and exhibits im-
munomodulatory effects [5]. The efﬁcacy of ﬁngolimod has
been demonstrated in clinical trials in patients with RRMS
[6–8]. However, ﬁngolimod is known to cause a transient re-
duction in heart rate (HR), which typically occurs within
6 h of dosing [9, 10]. This is thought to be due to the agonistic
activity of ﬁngolimod phosphate (ﬁngolimod-P; the active
metabolite of ﬁngolimod) at S1P1 and/or S1P3 receptors
on atrial myocytes, resulting in activation of the G
protein-coupled inwardly rectifying potassium (GIRK)
channel [11–17]. This acute negative chronotropic effect
caused by ﬁngolimod has led to a recommendation in the
prescribing information to monitor all patients for at least
6 h after the ﬁrst dose [4].
Amiselimod (also known as MT-1303) is an oral selective
S1P1 receptor modulator which is currently being developed
for the treatment of various autoimmune diseases.
Amiselimod is converted to its active metabolite, amiselimod
phosphate (amiselimod-P) in vivo and, unlike ﬁngolimod-P,
amiselimod-P has little agonistic activity at human S1P3
receptors [18]. In addition, amiselimod-P has shown a signif-
icantly attenuated potential to activate the GIRK channel in
human atrial myocytes compared with ﬁngolimod-P in an
in vitroGIRK channel assay [18]. The favourable cardiac safety
proﬁle of amiselimod has also been demonstrated in human
subjects: In a phase I multiple ascending dose study in
healthy subjects, no clinically signiﬁcant negative
chronotropic/dromotropic effects were observed at doses up
to 0.75 mg [18]. In the phase II study, which enrolled more
than 400 patients with RRMS, amiselimod up to 0.4 mg has
shown a benign safety proﬁle in addition to its superior efﬁ-
cacy to the placebo control [19].
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The aim of the present phase I study was further to exam-
ine and characterize the cardiac effects of amiselimod in
healthy subjects. For this purpose, the safety and tolerability
of two selected doses of amiselimod were evaluated and com-
pared with placebo (in a double-blind manner) and open-
label ﬁngolimod (0.5 mg; an approved therapeutic dose) as
an active control. The anticipated therapeutic dose of
amiselimod was considered to be 0.4 mg, whereas 0.8 mg
was chosen as a supratherapeutic dose [18, 19]. As the
potential negative chronotropic/dromotropic and inotropic
effects were of particular interest, frequent Holter electrocar-
diogram (ECG) and echocardiography assessments were
performed throughout the study (see Methods for details).
In addition, the potential pulmonary effect was assessed by
pulmonary function testing using spirometry. Other safety
and tolerability parameters, including vital signs, 12-lead
ECG, safety laboratory values and adverse events (AEs), were
also evaluated.
Methods
Subject selection
Healthy males (≥60 kg) and females (≥50 kg) of
nonchildbearing potential, aged 18–55 years with a body
mass index (BMI, Quetelet index) of 18–30 kg m–2, were eligi-
ble for the study. Subjects were required to have normal or no
clinically signiﬁcant 12-lead ECG ﬁndings, with a HR of
50–85 bpm and corrected QT interval using the Fridericia for-
mula (QTcF) of ≤450 ms at screening, Day 2 and at predose
on Day 1. Subjects were also required to have no clinically sig-
niﬁcant abnormalities in the 24-h Holter ECG at screening,
including an ectopic beat rate of less than 0.5% of total beats
and no second-degree or higher atrioventricular (AV) block
(occasional nocturnal Mobitz type I AV block was accept-
able). Vital signs were required to be within normal ranges,
including systolic blood pressure (90–140 mmHg) and dia-
stolic blood pressure (50–90 mmHg). Subjects were excluded
if they had taken any prescribed or nonprescribed medica-
tions within 14 days prior to the ﬁrst dose administration, if
they had ever taken any S1P receptor modulator and if they
had any evidence or history of clinically relevant diseases,
including endocrine, thyroid, hepatic, respiratory, gastroin-
testinal, renal or cardiovascular diseases; eye disorders; or a
history of psychiatric/psychotic disorders, tuberculosis or
alcohol/drug abuse. Other exclusion criteria included
positive tests for pregnancy, hepatitis B and C, and human
immunodeﬁciency virus (type 1 or 2); negative test for herpes
zoster/varicella immunoglobulin G; any clinically relevant
physical ﬁndings or safety laboratory values at screening or
Day 2; and lymphocyte counts <1.00 × 109 l–1 at screening
or Day 2.
Study design and treatments
This was a single-centre, randomized, parallel-group, par-
tially blinded, placebo-controlled, multiple oral dose clinical
study. It consisted of the screening period (Days 28 to 3),
the conﬁnement period (Days 2 to 30) and the follow-up
period (Days 35 to 77) (Figure S1). Following the screening,
eligible subjects were admitted to the clinical unit on
Day 2, where they remained until Day 30. The consump-
tion of food or drink containing alcohol was not allowed
in the 48 h before screening, until completion of Day 30
post-treatment assessments. Food or drink containing caf-
feine and methylxanthine (e.g. coffee, tea, cola, energy
drinks or chocolates) was also banned in the 36 h before
Day 2, until completion of Day 30. Baseline assessments
were conducted on Day 2 (for echocardiography and spi-
rometry), Day 1 (for Holter ECG) and at predose on Day
1 (for 12-lead ECG and lymphocyte count). Follow-up as-
sessments were conducted on Days 35, 42, 56 and 77. On
Day 42, all subjects were required to stay in the unit for
24-h Holter ECG. All Holter data were analysed centrally
and reported by independent, treatment-blind board-
certiﬁed cardiologists at Quintiles Cardiac Safety Services
(Mumbai, India).
On Day 1, all eligible subjects received a single-blinded
dose of placebo and were then randomized (in a 1:1:1:1 ratio)
to receive either amiselimod 0.4 mg, amiselimod 0.8 mg,
placebo matching to amiselimod or ﬁngolimod 0.5 mg. After
conﬁrmation of study eligibility on Day 1, randomized
subjects received a once-daily dose of the study medication
at approximately the same time in the morning of Days 1 to
28. Amiselimod and its matching placebo were administered
in a double-blind manner, whereas ﬁngolimod was adminis-
tered in an open-label manner. The lymphocyte and white
blood cell counts data were blinded at all postdose time-
points to all study personnel (except safety laboratory staff)
during the study. The trial was registered with EudraCT, num-
ber 2014–001520-29.
The study was conducted at a single study site (Covance
CRU Ltd., Leeds, UK) in accordance with the 2013 (Fortaleza)
revision of the 1964 Declaration of Helsinki, Good Clinical
Practice as required by the International Conference on
Harmonization guidelines, applicable regional and local
legislation, and standard operating procedures in place at
Mitsubishi Tanabe Pharma Europe Ltd. The study was ap-
proved by the ethics committee [the National Research Ethics
Service (NRES) Committee North East, York, UK (reference
number 14/NE/0139)] and regulatory authority [the Medi-
cines and Healthcare products Regulatory Agency (MHRA),
London, UK]. All subjects provided written informed consent
prior to screening.
Study assessments
Chronotropic and dromotropic effects were evaluated using
continuous, 24-h Holter ECG (M3R, 3-channel Holter re-
corder, Global Instrumentation, Manlius, NY, USA) on Days
1 (baseline), 1, 2, 7, 14, 21, 28 and 42. On eachHolter assess-
ment day, the recording was started 1 h prior to the dosing
time and therefore included the 1 h predose interval and 23
hourly postdose intervals. For Day 42 in the follow-up period,
Day 1 dosing time was used to deﬁne hourly intervals. Mean
hourly HR was derived from the Holter recording as the
average HR at each hourly interval. All arrhythmic events
detected by Holter ECG were analysed consistently as per
the Holter Alert Criteria, which consist of 27 predeﬁned
arrhythmic parameters (Table S1). Echocardiography (two-di-
mensional and Doppler) was performed on Days 2 (base-
line), 1, 14, 28 and 42 to measure stroke volume (SV),
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cardiac output (CO), systemic vascular resistance (SVR) and
ejection fraction (EF). Pulmonary function was evaluated
using spirometry onDays2 (baseline), 13, 27 and 35 tomea-
sure the forced expiratory volume in 1 s (FEV1), forced vital ca-
pacity (FVC), forced expiratory ﬂow at 25% to 75% of forced
vital capacity (FEF25–75) and the percentage of the vital capac-
ity that is expired in the ﬁrst second of maximal expiration
(FEV1/FVC). As a pharmacodynamic parameter, lymphocyte
count was measured on Day 1 (at predose as baseline and 4,
8, 12, 16 h postdose), Day 2 (24 h), Day 7 (144, 148, 152,
156 and 160 h), Day 8 (168 h), Day 14 (312, 316, 320,
324 and 328 h), Day 15 (336 h), Day 21 (480, 484, 488,
492 and 496 h), Day 22 (504 hs), Day 28 (648, 652, 656,
660 and 664 h), Day 29 (672 h), Day 35 (816 h), Day 42
(984 h), Day 56 (1320 h) and Day 77 (1824 h). To measure
the concentrations of amiselimod/amiselimod-P in plasma,
blood samples were collected at the same time points as
lymphocyte counts. Blood samples for the measurement of
ﬁngolimod/ﬁngolimod-P in whole blood were taken at
predose (i.e. trough concentration) on Day 1, Day 2 (24 h),
Day 7 (144 h), Day 14 (312 h), Day 21 (480 h), Day 28
(648 h), Day 35 (816 h), Day 42 (984 h), Day 56 (1320 h)
and Day 77 (1824 h) (see Supporting Information for ana-
lytical methods). Other safety and tolerability parameters,
including vital signs, 12-lead ECG (HR, RR, PR, QRS, QT
and QTcF intervals), safety laboratory values and AEs, were
also assessed during the study.
Statistical analyses
Mean hourly HRs from 1 h predose to 23 h postdose intervals
were analysed as a repeated measure using a generalized lin-
ear mixed model, including a ﬁxed effect of treatment-by-
hour-by-visit and baseline mean hourly HR (at predose on
Day1) as a covariate. A Kronecker product correlation struc-
ture was used to model the within-subject variance covari-
ance errors. The Kenward–Roger approximation was used to
estimate the denominator degrees of freedom. Least squares
(LS) means (in mean hourly HRs) vs. the hour, together
with 95% conﬁdence bands, were plotted. Negative
chronotropic effects were also evaluated using nadir (1–6 h),
nadir (1–12 h), nadir (12–23 h) and nadir (1–23 h), which
were deﬁned as the lowest mean hourly HR at each postdose
time period on each day. Changes from baseline in nadirs,
where baseline was the derived parameters on Day 1, were
analysed using the mixed model for repeated measures
(MMRM), including treatment and scheduled visit as ﬁxed ef-
fects, the corresponding baseline-derived parameter on Day
1 as a covariate, and treatment-by-visit and baseline-by-visit
interactions. An unstructured correlation structure was used
to model the within-subject variance covariance errors.
P-values on treatment differences vs. placebo by visit were cal-
culated. No multiplicity adjustments were made as this was
an exploratory phase I study. The negative dromotropic effect
was evaluated using arrhythmic parameters deﬁned in the
Holter Alert Criteria (Table S1), which were summarized
using descriptive statistics. For the inotropic and pulmonary
assessments, observed values in all predeﬁned parameters
(SV, CO, SVR and EF in echocardiography, and FEV1, FVC,
FEF25–75 and FEV1/FVC in spirometry) were summarized at
each scheduled visit by treatment groups using descriptive
statistics.
Pharmacodynamic and other safety assessments were
summarized using appropriate descriptive statistics.
Pharmacokinetic parameters, including maximum plasma
concentration (Cmax) and area under the plasma
concentration–time curve after administration (AUCτ), were
calculated for amiselimod/amiselimod-P. A half-life (t½) was
calculated for amiselimod/amiselimod-P and ﬁngolimod/
ﬁngolimod-P. Pharmacokinetic parameters were derived by
noncompartmental (linear–linear model) analysis using
WinNonlin® Professional version 6.3 (Pharsight, Princeton,
NJ, USA) and summarized using descriptive statistics. Nadir
(1–6 h) mean hourly HRs were plotted against nadir lym-
phocyte counts at postdose on Day 1 on a scatter plot with
a regression line for each treatment, with 80% conﬁdence
bands. The same analysis was performed by plotting the
lowest nadir (1–6 h) mean hourly HRs vs. nadir
lymphocyte counts during the 28-day treatment period.
All statistical analyses were conducted using SAS version
9.2 or later.
Sample size was not based on a formal statistical calcula-
tion because this was a phase I exploratory study. The
sample size was planned primarily to characterize
the chronotropic/dromotropic and inotropic effects of
amiselimod. A total of 80 subjects (20 per treatment group)
were considered sufﬁcient for this purpose.
Results
Study population
A total of 81 subjects were randomized to the amiselimod
0.4 mg (n = 21), amiselimod 0.8 mg (n = 19), placebo (n = 21)
and ﬁngolimod 0.5 mg (n = 20) groups. Two subjects random-
ized in the amiselimod 0.4 mg group were withdrawn from
the study before receiving the amiselimod dose (one owing
to an AE on Day 1 and one because of a low HR at predose
on Day 1). Therefore, 79 subjects were included in the safety
population, with 19, 19, 21 and 20 subjects in the
amiselimod 0.4 mg, amiselimod 0.8 mg, placebo and
ﬁngolimod groups, respectively (Table 1). Three subjects were
withdrawn from the study after Day 1: one in the ﬁngolimod
group was withdrawn on Day 1 owing to a serious AE (SAE)
(see Tables 3 and 4 for more details), one in the ﬁngolimod
group was lost to follow-up on Day 44 and one in the placebo
group withdrew consent on Day 4. Demographics and base-
line characteristics were generally well balanced across the
treatment groups. Overall, the mean age of the subjects was
34 years (range 19–55 years), the mean weight was 79.0 kg
(range 60.8–103.8 kg) and the mean BMI was 25.1 kg m–2
(range 19.9–29.5 kg m–2). All subjects were male.
Overview of changes in mean hourly HR over
time
The mean hourly HR data from Day 1 to Day 42 are pre-
sented in Figure 1. Overall, there was no apparent disturbance
of the circadian rhythm of HR in either amiselimod groups or
the ﬁngolimod group compared with placebo. At baseline
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(Day 1), there were no notable differences in mean hourly
HR between any of the groups throughout the day. On Day
1, the mean hourly HR proﬁles for both amiselimod groups
were similar to that seen for the placebo group, which was
consistent with the proﬁles observed on Day 1. In the
ﬁngolimod group, a rapid decrease in mean hourly HR com-
pared with the placebo group was seen within the ﬁrst 6 h af-
ter dosing on Day 1 and HR remained reduced during the rest
of the day. On Day 2, a slight reduction in mean hourly HR
was seen throughout the day in both amiselimod groups
compared with placebo, although there was no sign of a rapid
reduction within the ﬁrst 6 h postdosing. In the ﬁngolimod
group, a marked reduction in mean hourly HR was still pres-
ent in the ﬁrst 6 h and no overlap of 95% conﬁdence intervals
(CIs) occurred with the placebo group throughout the day.
On Day 7, a decrease in mean hourly HR seemed to become
most apparent in both amiselimod groups compared with
placebo, which was largely limited within the ﬁrst 12 h after
dosing. Notably, the magnitude of the reduction was smaller
than that of the ﬁngolimod group at any time. On Day 14,
the pattern was similar to that seen on Day 7 for all groups.
On Day 21, the effects of both amiselimod doses in mean
hourly HR had mostly resolved. On Day 28, there was only
a small difference between the amiselimod and placebo
groups, whereas the effect of ﬁngolimod was still clearly visi-
ble, particularly during the ﬁrst 12 h of dosing. On Day 42
(14 days after the last dose), the mean hourly HR proﬁles for
all active treatment groups were similar to that seen in the
placebo group.
Nadir mean hourly HR
The changes from baseline in nadir mean hourly HRs at
prespeciﬁed time periods on each Holter assessment day
are presented in Figure 2. LS mean differences vs. placebo
are provided in Table 2. There was no signiﬁcant change
in nadir (1–6 h) mean hourly HR on Day 1 or 2 in either
of the amiselimod groups compared with placebo. The low-
est nadir (1–6 h) during the 28-day treatment period was
seen on Day 14 in the amiselimod 0.4 mg group (LS mean
difference 4.40 bpm, 95% CI 7.15, 1.66) and Day 7 in
the amiselimod 0.8 mg group [3.85 bpm (6.58, 1.11)]
compared with placebo. Both returned to baseline by Day
28. In the ﬁngolimod group, a signiﬁcant reduction in na-
dir (1–6 h) occurred on Day 1 [6.49 bpm (8.95, –4.02)]
compared with placebo, which then became the lowest
on Day 2 [9.18 bpm (12.42, 5.93)]. Although it
gradually increased between Days 7 and 21, a difference
from placebo was still evident on Day 28 (LS mean differ-
ence 3.39 bpm, 95% CI –6.46, 0.32). Nadir (1–12 h)
followed a similar pattern to nadir (1-6 h) in all groups,
as nadir (1–12 h) was generally seen within 6 h postdose.
The effect of both amiselimod doses, when evaluated by
nadir (1–6 h) and nadir (1–12 h), was consistently smaller
than that of ﬁngolimod throughout the 28-day treatment
period. It should be noted that the magnitude of the max-
imum HR reduction observed in both amiselimod groups
over 28 days was smaller than that seen with ﬁngolimod
on Day 1.
The amiselimod 0.4 mg group showed a small reduction
(LS mean difference 2.40 bpm, 95% CI 3.88, 0.92) in na-
dir (1–23 h) mean hourly HR compared with placebo on Day
1. A similar difference was observed on Days 2, 7 and 14, with
a return to baseline on Day 28. Both amiselimod 0.8 mg
[4.03 bpm (5.51, 2.55)] and ﬁngolimod [3.51 bpm
(4.97, 2.04)] groups showed a comparable level of reduc-
tion in nadir (1–23 h) on Day 1, which was larger than that
in the amiselimod 0.4 mg group. Nadirs (1–23 h) in both
groups were slightly lower on Days 2, 7 and 14 than on Day
1 but no notable difference was observed on Day 21 com-
pared with the amiselimod 0.4 mg group. Nadir (12–23 h)
followed a generally similar pattern to nadir (1–23 h) in all
groups.
Comprehensive analysis of rhythm
abnormalities as per the Holter Alert Criteria
HR and cardiac rhythm were assessed as per the Holter Alert
Criteria (Table 3). Mean hourly HR analysis is not sensitive
Table 1
Subject demographics and baseline characteristics
Placebo (N = 21)
Amiselimod
0.4 mg (N = 19)
Amiselimod
0.8 mg (N = 19)
Fingolimod
0.5 mg (N = 20) Total (N = 79)
Age (years) Mean (SD) 32.9 (10.1) 38.5 (11.5) 30.3 (8.3) 34.2 (8.5) 34.0 (9.9)
Range (20, 53) (23, 55) (22, 49) (19, 52) (19, 55)
Racea White 17 (81.0%) 15 (78.9%) 14 (73.7%) 16 (80.0%) 62 (78.5%)
Black or African
American
2 (9.5%) 1 (5.3%) 1 (5.3%) 4 (20.0%) 8 (10.1%)
Asian 1 (4.8%) 0 (0.0%) 3 (15.8%) 0 (0.0%) 4 (5.1%)
Other 1 (4.8%) 3 (15.8%) 1 (5.3%) 0 (0.0%) 5 (6.3%)
Weight (kg) Mean (SD) 78.35 (10.05) 78.53 (9.41) 76.97 (12.11) 82.16 (11.44) 79.03 (10.76)
Range (62.8, 102.0) (64.3, 96.5) (60.8, 103.8) (62.9, 102.4) (60.8, 103.8)
BMI (kg m–2) Mean 25.22 (2.37) 24.94 (2.68) 24.09 (2.86) 26.16 (2.42) 25.12 (2.64)
Range (21.8, 28.9) (21.2, 29.5) (19.9, 29.3) (22.2, 29.4) (19.9, 29.5)
BMI, body mass index; SD, standard deviation
aPercentages are based on the number of subjects in each treatment group. All subjects were male.
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Figure 1
Mean hourly heart rate (HR) in all treatment groups on Days 1 (baseline), 1, 2, 7, 14, 21, 28 and 42. Results are shown as the least squares (LS)
mean, with 95% conﬁdence bands indicated in faded colours. Note: A temporary increase in mean hourly HR was observed at approximately
3–4 h and 10–11 h after dosing in all groups, which corresponded to lunch and dinner mealtimes. The increase was larger for the evening than
the daytime meal because subjects were allowed to move off the ward for dinner, whereas they were required to remain on their beds for lunch
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enough to detect ‘short-term’ bradycardia episodes. To iden-
tify such events, three criteria for short-term bradycardia
were deﬁned and evaluated: No episodes of ‘pause ≥3 s’ or
‘marked bradycardia episode at HR ≤30 bpm lasting ≥15 s’
were reported in any treatment group. ‘Bradycardia mini-
mum at HR ≤40 bpm lasting ≥30 s’ was seen more frequently
in the ﬁngolimod group compared with both amiselimod
groups (Table 3) but none of these episodes were considered
to be clinically relevant by the investigator.
All rhythm abnormalities recorded on Holter ECG were
also reviewed thoroughly. No signiﬁcant arrhythmic events
were observed in any treatment group, except for one subject
in the ﬁngolimod group; a 39-year-old Caucasian male sub-
ject reported clinically signiﬁcant Mobitz Type I AV block
(382 episodes), 2:1 AV block (89 episodes) and exacerbation
of ﬁrst-degree AV block (PR interval prolongation was also
conﬁrmed in the 12-lead ECG: 224 ms at baseline, 332 ms at
6 h postdose, 344 ms at 12 h postdose) on Day 1, which led
to withdrawal from the study medication (see Other safety
and tolerability assessments below). No ﬁrst- or second-degree
AV block of clinical concern occurred in either amiselimod
group. Of note, no ventricular or supraventricular tachyar-
rhythmia of clinical signiﬁcance was detected in any group.
Potential inotropic effect assessed by
echocardiography
Figure 3 shows the mean SV, CO, SVR and EF on Days 2, 1,
14, 28 and 42. None of these parameters showed clinically
meaningful changes from baseline (Day 2) in either
amiselimod group (Table S2). By contrast, a slightly larger de-
crease from baseline in the CO was seen in the ﬁngolimod
group on Day 1 (mean –0.720 l min–1) and Day 14 (0.839 l
min–1). However, as the mean CO values were above 3.9 l
min–1 (reference range 4.0–8.0 l min–1) on both days, these
changes were not considered to be clinically signiﬁcant.
Potential pulmonary effect assessed by
spirometry
Figure S2 shows the mean FEV1, FVC, FEF25–75 and FEV1/FVC
on Days 2, 13, 27 and 35. There were no clinically relevant
changes observed in any treatment group.
Figure 2
Nadir mean hourly heart rate at each postdose time. Results are shown as least squares mean  standard error. Dashed curves represent the
changes during the follow-up period. *P < 0.05
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Pharmacokinetic assessments
The pharmacokinetic parameters for amiselimod and
amiselimod-P are presented in Table S3. The mean Cmax and
AUCτ of amiselimod and amiselimod-P in the amiselimod
0.8 mg group were approximately double those in the
amiselimod 0.4 mg group on each study day. The mean t½
Table 2
Negative chronotropic effect assessed by nadir mean hourly heart rate compared with placebo
LS mean difference
(95% CI) vs. placebo
Amiselimod
0.4 mg (N = 19)
Amiselimod
0.8 mg (N = 19)
Fingolimod
0.5 mg (N = 20)
Day 1
Nadir (1–6 h) 1.11 (1.38, 3.59) 0.72 (1.79, 3.22) –6.49 (8.95, 4.02)
Nadir (1–12 h) –0.69 (3.22, 1.84) –2.52 (5.05, 0.01) –5.83 (8.33, 3.34)
Nadir (12–23 h) –2.31 (3.74, 0.88) –3.69 (5.12, 2.26) –3.45 (4.86, 2.03)
Nadir (1–23 h) –2.40 (3.88, 0.92) –4.03 (5.51, 2.55) –3.51 (4.97, 2.04)
Day 2
Nadir (1–6 h) –1.16 (4.43, 2.12) –3.20 (6.49, 0.10) –9.18 (12.42, 5.93)
Nadir (1–12 h) –2.84 (5.67, 0.00) –5.59 (8.43, 2.75) –8.42 (11.23, 5.62)
Nadir (12–23 h) –2.58 (4.06, 1.11) –3.88 (5.35, 2.40) –4.56 (6.02, 3.10)
Nadir (1–23 h) –2.76 (4.18, 1.33) –4.13 (5.56, 2.70) –4.69 (6.10, 3.28)
Day 7
Nadir (1–6 h) –3.24 (5.94, 0.55) –3.85 (6.58, 1.11) –6.73 (9.42, 4.04)
Nadir (1–12 h) –2.94 (5.49, 0.39) –3.77 (6.32, 1.22) –5.27 (7.81, 2.73)
Nadir (12–23 h) –2.47 (4.66, 0.27) –4.92 (7.12, 2.71) –4.19 (6.39, 1.99)
Nadir (1–23 h) –2.70 (4.87, 0.54) –5.11 (7.28, 2.93) –4.28 (6.45, 2.12)
Day 14
Nadir (1–-6 h) –4.40 (7.15, 1.66) –3.42 (6.18, 0.66) –5.33 (8.07, 2.59)
Nadir (1–12 h) –2.96 (5.62, 0.29) –2.43 (5.10, 0.24) –5.85 (8.52, 3.19)
Nadir (12–23 h) –3.39 (5.20, 1.57) –4.31 (6.13, 2.49) –4.22 (6.04, 2.41)
Nadir (1–23 h) –3.37 (5.22, 1.52) –4.37 (6.23, 2.52) –4.23 (6.08, 2.38)
Day 21
Nadir (1–6 h) –3.18 (6.26, 0.10) –0.96 (4.06, 2.14) –4.13 (7.20, 1.05)
Nadir (1–12 h) –2.50 (5.44, 0.44) –0.91 (3.86, 2.03) –3.96 (6.90, 1.01)
Nadir (12-23 h) –1.68 (4.09, 0.72) –1.87 (4.28, 0.54) –1.35 (3.75, 1.06)
Nadir (1–23 h) –1.82 (4.19, 0.55) –2.06 (4.44, 0.31) –1.50 (3.87, 0.88)
Day 28
Nadir (1–6 h) –1.00 (4.08, 2.07) –1.67 (4.76, 1.42) –3.39 (6.46, 0.32)
Nadir (1–12 h) –1.23 (4.17, 1.70) –1.93 (4.87, 1.01) –3.68 (6.61, 0.74)
Nadir (12–23 h) –1.18 (3.45, 1.09) –1.20 (3.47, 1.08) –0.89 (3.16, 1.38)
Nadir (1–23 h) –1.33 (3.59, 0.93) –1.41 (3.67, 0.86) –1.00 (3.26, 1.26)
Day 42
Nadir (1–6 h) –0.22 (3.29, 2.85) –0.12 (3.21, 2.97) 0.85 (2.25, 3.94)
Nadir (1–12 h) 0.51 (2.34, 3.37) 0.80 (2.06, 3.66) 1.44 (1.45, 4.32)
Nadir (12–23 h) –0.49 (2.62, 1.64) –0.80 (2.93, 1.34) 1.75 (0.40, 3.91)
Nadir (1–23 h) –0.64 (2.79, 1.51) –1.03 (3.18, 1.12) 1.63 (0.55, 3.80)
Nadir (1–6 h), nadir (1–12 h) and nadir (1–23 h) are the lowest mean hourly heart rate from the dosing time to 6 h, 12 h and 23 h postdose, re-
spectively. Nadir (12–23 h) is the lowest mean hourly heart rate from 12 h postdose to 23 h postdose. Least squares (LS) means and conﬁdence
intervals (CIs) are based on a mixed model for repeated measures, with treatment and scheduled visits as ﬁxed effects, baseline-derived parameter
(Day 1) as a covariate and treatment-by-visit and baseline-by-visit interactions.
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Table 3
Negative chronotropic and dromotropic effects assessed by the Holter Alert Criteria
Placebo
(N = 21)
Amiselimod
0.4 mg (N = 19)
Amiselimod
0.8 mg (N = 19)
Fingolimod
0.5 mg (N = 20)
Bradycardiaa
Bradycardia minimum at heart rate ≤40 bpm lasting ≥30 s
Baseline (Day 1) 0 1 (5.3%) 0 1 (5.0%)
Day 1 0 1 (5.3%) 0 2 (10.0%)
Day 2 0 1 (5.3%) 0 4 (20.0%)
Day 7 0 1 (5.3%) 1 (5.3%) 2 (10.0%)
Day 14 0 0 1 (5.3%) 1 (5.0%)
Day 21 0 1 (5.3%) 1 (5.3%) 0
Day 28 0 0 0 0
Day 42 0 0 0 0
Atrioventricular (AV) blockb
First degree AV block (PR interval >220 ms)
Baseline (Day 1) 0 0 1 (5.3%) 2 (10.0%)
Day 1 0 0 1 (5.3%) 1c (5.0%)
Day 2 0 0 1 (5.3%) 1c (5.0%)
Day 7 1 (4.8%) 0 0 0
Day 14 1 (4.8%) 0 0 0
Day 21 0 0 0 1 (5.0%)
Day 28 1 (4.8%) 0 0 0
Day 42 2 (9.5%) 0 0 0
Mobitz Type I (Wenckebach) 2nd degree AV block
Baseline (Day 1) 0 2 (10.5%) 2 (10.5%) 0
Day 1 0 1 (5.3%) 2 (10.5%) 1c (5.0%)
Day 2 0 0 1 (5.3%) 1c (5.0%)
Day 7 0 1 (5.3%) 0 0
Day 14 0 0 0 0
Day 21 0 0 0 0
Day 28 2 (9.5%) 0 0 0
Day 42 2 (9.5%) 0 0 0
2:1 AV block
Baseline (Day 1) 0 0 0 0
Day 1 0 0 0 1c (5.0%)
Day 2 0 0 0 0
Day 7 0 0 0 0
Day 14 0 0 0 0
Day 21 0 0 0 0
Day 28 0 0 0 0
Day 42 0 0 0 0
The number of patients was the count of unique patients with at least one valid observation. Data shown as numbers (%)
a‘Marked bradycardia minimum at heart rate ≤30 bpm lasting ≥15 s’ and ‘pause ≥3 s’ were not reported in any treatment group
b‘Mobitz Type II 2nd degree AV block’, ‘high-grade AV block’ and ‘complete heart block’ were not reported in any treatment group
cOne subject reported clinically signiﬁcant Mobitz Type I AV block (382 episodes), 2:1 AV block (89 episodes) and exacerbation of ﬁrst-degree AV
block (PR interval >330 ms at postdose) on Day 1, which led to the withdrawal from the study medication
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was similar in both amiselimod groups: 444 h for amiselimod
and 443 h for amiselimod-P in the amiselimod 0.4 mg group,
and 432 h for amiselimod and 437 h for amiselimod-P in the
0.8 mg group. The mean t½ of ﬁngolimod was 255 h but the
mean t½ of ﬁngolimod-P could not be calculated owing to
its concentration below the lower limit of quantiﬁcation on
Days 42, 56 and 77.
Pharmacodynamic assessments
Peripheral lymphocyte counts decreased in a dose-dependent
manner in the amiselimod groups during the 28-day treat-
ment period (Figure 4A). The reduction in the amiselimod
0.8 mg group followed a generally similar pattern to that seen
in the ﬁngolimod group, whereas the reduction seen in the
amiselimod 0.4 mg group was more gradual. On Day 28
(648 h), the mean lymphocyte counts were 0.70 × 109 l–1,
0.55 × 109 l–1 and 0.63 × 109 l–1 in the amiselimod 0.4 mg,
0.8 mg and ﬁngolimod groups, respectively (1.99 × 109 l–1 in
placebo), which corresponded to approximately 61%, 73%
and 68%, respectively, of lymphocyte reductions from
baseline values. No subjects in any treatment group met the
protocol-deﬁned withdrawal criterion of lymphocytopenia
(i.e. absolute lymphocyte count ≤0.20 × 109 l–1, conﬁrmed in
a subsequent repeat test). After the last drug administration,
the ﬁngolimod group showed a faster recovery of lymphocyte
count than both amiselimod groups, which would have been
in line with the differences in the elimination t½ between
these two compounds. On the last follow-up day (Day 77;
1824 h), the mean lymphocyte counts returned to 84.3%,
77.1% and 59.8% of baseline values in the ﬁngolimod group,
and the amiselimod 0.4 mg and 0.8 mg groups, respectively.
Relationship between the pharmacodynamic
effect and negative chronotropic effect
During the ﬁrst day of drug administration, all active treat-
ment groups followed a generally normal circadian rhythm
of lymphocytes (as shown in the placebo group) and the
mean lymphocyte counts remained within the reference
range (0.99–2.99 × 109 l–1) (Figure 4B). However, the
Figure 3
Changes in echocardiography parameters over time. Echocardiography was performed on Days 2 (baseline), 1, 14, 28 and 42 to measure the
stroke volume, cardiac output, systemic vascular resistance and ejection fraction. Results are shown as mean  standard error. LLN, lower limit of
normal; ULN; upper limit of normal
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Figure 4
Changes in peripheral lymphocyte counts (A) during all study periods and (B) on Day 1. Results are shown as mean + standard deviation. The ref-
erence range for lymphocyte counts is 0.99–2.99 × 109 l–1. LLN, lower limit of normal; ULN, upper limit of normal
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reduction in lymphocyte counts suggested similar but
slightly different pharmacodynamic effects of amiselimod
and ﬁngolimod on Day 1. To evaluate the potential relation-
ship between the onset of the pharmacodynamic effect and
the negative chronotropic effect caused by each drug, we
compared nadir lymphocyte counts (1–24 h) and nadir
(1–6 h) mean hourly HR on Day 1 (Figure 5A). Overall,
neither dose of amiselimod showed a clear relationship be-
tween mean hourly HRs and lymphocyte counts, which was
similar to the ﬁnding in the placebo group. By contrast, the
ﬁngolimod group presented lower mean hourly HRs with
decreasing lymphocyte counts following the ﬁrst dose. We
further explored whether there was a relationship between
the maximum pharmacodynamic effect and negative
Figure 5
Relationship between the pharmacodynamic effect and negative chronotropic effect. Nadir lymphocyte counts and nadir (1–6 h) mean hourly
heart rates in all subjects (A) on Day 1 and (B) during the 28-day treatment period are plotted. Results are shown asmean 80% conﬁdence bands
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chronotropic effect during the 28-day treatment period
(Figure 5B). Over 28 days, the lowest nadir (1–6 h) mean
hourly HR was generally higher in both amiselimod groups
compared with the ﬁngolimod group, regardless of the values
of nadir lymphocyte counts. This indicated that there was a
notable difference in the negative chronotropic effect caused
by the two tested drugs when the similar pharmacodynamic
effect on lymphocyte count was achieved.
Other safety and tolerability assessments
Both amiselimod doses administered once daily for 28 days
were well tolerated in healthy subjects. Most subjects
experienced at least one treatment-related AE during the
study, although there was no notable difference between the
groups (Table 4). No SAEs were reported and there was no
withdrawal due to an AE in either of the amiselimod groups.
Fingolimod was also generally well tolerated, although there
was one treatment-related SAE (i.e. clinically signiﬁcant 2:1
AV block) in the ﬁngolimod group (see Comprehensive analysis
of rhythm abnormalities above). This event was judged as mild
in intensity as no symptoms of cardiac origin were reported.
Apart from this case, there were no AEs and no clinically
signiﬁcant ﬁndings in vital signs, 12-lead ECG or safety labo-
ratory values in any treatment group. Regarding QTcF pro-
longation, three subjects (one in each active treatment
group) had a QTcF of 450–480 ms at one postdose time point
during the study. No subjects had a QTcF of >480 ms at any
time point. Changes from baseline in QTcF of >30 ms
occurred in all groups, with nine subjects (42.9%) in the
placebo group, four (21.1%) in the amiselimod 0.4 mg group,
eight (42.1%) in the amiselimod 0.8 mg group and eight
(40.0%) in the ﬁngolimod group. No subjects in any group
had a QTcF prolongation of >60 ms from baseline (Table S4).
Discussion
This study was designed to characterize the cardiac safety proﬁle
of amiselimod in healthy subjects. The frequentHolter ECG and
echocardiography assessments allowed for a comprehensive
evaluation of the potential negative chronotropic/dromotropic
and inotropic effects of amiselimod. An anticipated clinical dose
(0.4 mg) of amiselimod administered once daily for 28 days
achieved>60% of lymphocyte reductions from baseline, which
Table 4
Summary of treatment-emergent adverse events with an incidence of ≥10% (by System Organ Class)
Placebo
(N = 21)
Amiselimod
0.4 mg (N = 19)
Amiselimod
0.8 mg (N = 19)
Fingolimod
0.5 mg (N = 20)
Summary of treatment-emergent adverse events (TEAEs)
Total number of TEAEs 68 59 74 89
Subjects with ≥1 TEAE 18 (85.7%) 13 (68.4%) 14 (73.7%) 19 (95.0%)
Subjects with ≥1 serious TEAE 0 0 0 1a (5.0%)
Subject withdrawn due to TEAE 0 0 0 1a (5.0%)
Frequent TEAEs affecting ≥ 10% of subjects in any treatment group
General disorders and administration site conditions 4 (19.0%) 7 (36.8%) 10 (52.6%) 9 (45.0%)
Nervous system disorders 10 (47.6%) 5 (26.3%) 6 (31.6%) 7 (35.0%)
Gastrointestinal disorders 8 (38.1%) 5 (26.3%) 4 (21.1%) 6 (30.0%)
Skin and subcutaneous tissue disorders 4 (19.0%) 6 (31.6%) 6 (31.6%) 7 (35.0%)
Respiratory, thoracic and mediastinal disorders 6 (28.6%) 4 (21.1%) 8 (42.1%) 4 (20.0%)
Infections and infestations 4 (19.0%) 5 (26.3%) 5 (26.3%) 3 (15.0%)
Musculoskeletal and connective tissue disorders 3 (14.3%) 3 (15.8%) 4 (21.1%) 5 (25.0%)
Cardiac disorders 2 (9.5%) 1 (5.3%) 3 (15.8%) 2a (10.0%)
Eye disorders 3 (14.3%) 0 1 (5.3%) 3 (15.0%)
Metabolism and nutrition disorders 2 (9.5%) 0 1 (5.3%) 3 (15.0%)
Ear and labyrinth disorders 1 (4.8%) 1 (5.3%) 1 (5.3%) 2 (10.0%)
Injury, poisoning and procedural complications 3 (14.3%) 0 1 (5.3%) 1 (5.0%)
Investigations 0 0 0 2 (10.0%)
Serious TEAEs
Cardiac disorders 0 0 0 1a (5.0%)
Data shown as numbers (%).
aOne subject reported clinically signiﬁcant Mobitz Type I AV block (382 episodes), 2:1 AV block (89 episodes) and exacerbation of ﬁrst-degree AV
block (PR interval >330 ms at postdose) on Day 1, which led to withdrawal from the study medication
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is expected to show some immunomodulatory effects. A
supratherapeutic dose (0.8 mg) of amiselimod was included to
understand the safety margin of this compound in humans.
The addition of the ﬁngolimod group enabled us directly to
compare two selected doses of amiselimod with ﬁngolimod,
which is the only S1P receptor modulator currently on the mar-
ket. The data obtained for ﬁngolimod in the present study were
consistent with its known cardiac, pharmacodynamic and
exposure proﬁles [10, 17, 20].
The potential for a negative chronotropic effect of
amiselimod and ﬁngolimod was evaluated in detail by using
Holter ECG parameters; mean hourly HR and short-term
bradycardia deﬁned in the Holter Alert Criteria. All data
derived from these parameters clearly demonstrated a lower
risk of bradycardia in amiselimod, especially at the 0.4 mg
dose, when compared with ﬁngolimod. The difference was
most evident during the ﬁrst 6 h after administration on
Day 1, during which amiselimod showed no sign of the
ﬁrst-dose effects on HR. The lowest nadir (1–6 h) mean hourly
HR during the 28-day treatment period was observed on Day
7 or 14 in the amiselimod groups. However, the magnitude of
reduction was still smaller than that seen in the ﬁngolimod
group on Day 1, during which cardiac safety monitoring for
at least 6 h is recommended [4]. The difference in the negative
chronotropic effect between the two drugs was also evident
when a similar pharmacodynamic effect was observed over
28 days. The short-term bradycardia episodes of ‘pause ≥3 s’
and ‘marked bradycardia episode at HR ≤30 bpm lasting
≥15 s’ were considered to be medically important as subjects
could be symptomatic due to these events. However, no such
episodes were reported in any treatment group during the
study. The number of AEs, including cardiac disorders, in
each amiselimod group was similar to that in the placebo
group.
No AV block of clinical concern was detected in either
amiselimod group but one subject in the ﬁngolimod group
was withdrawn owing to highly frequent 2:1 AV blocks.
To date, there have been no clinically signiﬁcant
AV blocks reported in amiselimod phase I and II studies
[18, 19]. All of these ﬁndings suggested that amiselimod
up to 0.8 mg is unlikely to induce any signiﬁcant
dromotropic effect in humans, although this hypothesis
needs to be further validated in large-scale and longer-
term studies. All of these data strongly indicate that,
unlike ﬁngolimod, patients treated with amiselimod would
not require any cardiac safety monitoring after starting
treatment.
It is known that S1P1 receptors expressed in ventricular
myocytes are involved in changes in cardiac contraction
[15, 21]. The present study was the ﬁrst in which an inotropic
effect of amiselimod was investigated in humans. The study
demonstrated that amiselimod up to 0.8 mg did not show
any change in the SV, CO, SVR or EF in healthy subjects. By
contrast, a slight decrease in the mean CO was seen in the
ﬁngolimod group on Days 1 and 14. This change is likely to
reﬂect the largest HR reduction observed on the same study
day in this group.
The mechanisms to explain these differences between
amiselimod and ﬁngolimod are not yet well characterized.
The previously published data from animal (rodent)
studies strongly suggested that the S1P3 receptor is
predominantly responsible for a transient bradycardia
caused by ﬁngolimod, which has an agonistic afﬁnity to
S1P1 and S1P3–5 receptor subtypes [11, 12, 22]. However,
recent clinical studies revealed that two selective S1P
receptor modulators, siponimod (BAF312) and ceraliﬁmod
(ONO-4641), did show a signiﬁcant HR reduction after the
ﬁrst dose in healthy human subjects, despite their lack of
S1P3 agonist activity [23, 24]. Thus, it should be noted that
pathogenesis of the cardiac signal transduction system in
animal models may not necessarily reﬂect that in humans
owing to species differences in basal HR, inherent ion channel
expression, the tissue distribution of S1P receptor subtypes or
a combination of these factors [23, 25–27]. Indeed, Rey et al.
indicated that the effects on HR and AV conduction are
caused via activation of the S1P1 receptor in guinea pigs as
well as in humans [26]. However, such effects in guinea pigs
did not completely mimic those in humans; even a high dose
of ﬁngolimod (0.1 mg kg–1 per 10 min, intravenously) and
ponesimod (30 mg kg–1, orally) did not lower the atrial rate
in guinea pigs [26, 27]. Mazurais et al. have shown that,
in humans, S1P1 receptor mRNA and protein are
strongly expressed in atrial, septal and ventricular
cardiomyocytes, whereas S1P3 receptor mRNA is only weakly
expressed both in atria and ventricles [28]. However,
further conﬁrmatory studies are necessary because strong
expression both of S1P1 and S1P3 receptors in human atrial
myocytes has also been reported [29]. It is our current
understanding that S1P1 agonists which do not bind to S1P3
receptors result in bradyarrhythmia in humans. However,
the possibility that S1P3 agonism alone could at least partially
contribute to this adverse effect in humans cannot be ruled
out at present [14–16].
Our preclinical studies have previously demonstrated a
slower conversion speed of amiselimod to its active metabo-
lite, amiselimod-P, in human cardiomyocytes as well as a
lower distribution of amiselimod-P in heart tissues in rats
compared with ﬁngolimod-P, both of which are likely to
contribute to a gradual internalization of the receptor com-
plex on atrial myocytes [18]. In addition, we have reported a
signiﬁcantly weaker potential of amiselimod-P to activate
the GIRK channel in human atrial myocytes compared with
ﬁngolimod-P [18]. Based on these ﬁndings, it is conceivable
that the different kinetics of S1P receptor occupancy and in-
ternalization may have an impact on the strength of the S1P
downstream signal related to GIRK channel activation. Inter-
estingly, unlike siponimod [23], these unique biological
characteristics of amiselimod seen in our preclinical studies
were well translated to human subjects, as demonstrated in
the present study. The negative chronotropic effect of
amiselimod was largely limited up to 12 h after dosing on
Days 7 and 14, which may reﬂect a low distribution of
amiselimod-P in the human heart. After 12 h, compensatory
mechanisms by the autonomic nervous systems may inter-
vene to prevent a signiﬁcant lowering of HR. The ﬁndings
in the present study were also consistent with those in our
previous phase I and II studies in healthy subjects and
patients with RRMS, which showed that amiselimod at doses
up to 0.75 mg (for 21 days in phase I) and up to 0.4 mg (for
24 weeks in phase II) were well tolerated and did not cause
any clinically relevant bradyarrhythmia [18, 19]. A long elim-
ination t½ (approximately 430–450 h) of both amiselimod
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and amiselimod-P in humans was also shown in the present
study, indicating that both will slowly accumulate to reach
their steady-state concentrations over a period of approxi-
mately 10 weeks, with more than 10-fold accumulation. As
it is known that a rapid increase in drug concentration trig-
gers GIRK-dependent signalling [26], this pharmacokinetic
proﬁle would be beneﬁcial to initiate amiselimod treatment;
an initial dose has little cardiac effect, and desensitization
can be expected to occur gradually over several weeks of accu-
mulation. Thus, amiselimod up to 0.8 mg was administered
safely, without the need for a dose titration regimen. By con-
trast, dose titration was required to attenuate HR reduction
following treatment initiation with other selective S1P recep-
tor modulators such as siponimod, ponesimod and ozanimod
(RPC-1063) [30–33].
The present study had some limitations. (i) This phase
I study involved a small number of healthy male subjects
at a single study site. A larger-scale study including
females would be necessary to conﬁrm these ﬁndings.
(ii) The duration of exposure in the study was limited to
28 days, so as not to compromise the safety of the sub-
jects. However, as the maximum HR reduction and its
recovery to baseline were conﬁrmed with both drugs, the
study duration was deemed sufﬁcient to evaluate the
differences between the two drugs on cardiac effects in
the acute to subacute phases. (iii) As a result of practical
limitations, placebo matching to ﬁngolimod was not avail-
able at the time of the study. Therefore, ﬁngolimod was
administered in an open-label manner, rendering the
study partially blinded. However, the primary aim of the
study was to evaluate the cardiac effects of amiselimod
and ﬁngolimod. The ‘objective’ cardiac parameters, such
as mean hourly HR, bradyarrhythmia episodes and echo-
cardiography parameters, were all assessed in a blinded
manner and without the investigator’s judgement. (iv)
Because of frequent Holter ECG assessment, a 12-lead
ECG was not performed intensively. Overall, there were
no consistent trends in the QTcF interval in any treat-
ment group. However, a thorough QT study is awaited,
to evaluate formally the potential effect of amiselimod in
QT prolongation. (v) As only trough concentrations of
ﬁngolimod and ﬁngolimod-P were measured, the relation-
ship between drug concentrations and lymphocyte counts
and/or HRs in each drug could not be fully explored.
However, a weaker negative chronotropic effect by
amiselimod was seen when a similar pharmacodynamic
effect was achieved.
In summary, the distinct cardiac safety characteristics of
amiselimod in humans were successfully demonstrated in
the present study. Unlike the observations with some other
S1P receptor modulators, there were no clinically signiﬁ-
cant effects on cardiac rhythm at either of the amiselimod
doses tested, especially within 6 h after the ﬁrst dose. A
wider safety margin of amiselimod 0.4 mg dose was also
clearly demonstrated. These results strongly suggest that
the 6-h cardiac safety monitoring required after the ﬁrst
dose of ﬁngolimod is considered unwarranted with the
use of amiselimod. To our knowledge, amiselimod is the
only drug in this class which can be administered without
the need of a dose titration regimen and cardiac safety
monitoring.
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